Filing Details

Accession Number:
0001562180-20-000454
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-21 16:18:50
Reporting Period:
2020-01-17
Accepted Time:
2020-01-21 16:18:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590877 Regenxbio Inc. RGNX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1346164 Curran Simpson C/O Regenxbio Inc.
9600 Blackwell Road, Suite 210
Rockville MD 20850
Svp, Product Development & Cto No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-17 1,622 $19.50 25,570 No 4 M Direct
Common Stock Acquisiton 2020-01-17 2,700 $22.00 28,270 No 4 M Direct
Common Stock Acquisiton 2020-01-17 800 $35.80 29,070 No 4 M Direct
Common Stock Disposition 2020-01-17 5,922 $50.00 23,148 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-01-17 800 $0.00 800 $35.80
Common Stock Stock Option (Right to Buy) Disposition 2020-01-17 2,700 $0.00 2,700 $22.00
Common Stock Stock Option (Right to Buy) Disposition 2020-01-17 1,622 $0.00 1,622 $19.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
40,450 2028-01-03 No 4 M Direct
22,519 2025-08-30 No 4 M Direct
13,378 2027-01-03 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  2. This transaction was executed in multiple trades at prices ranging from $50.00 to $50.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. The previously granted option, representing a right to purchase a total of 55,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2019, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.
  4. The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.
  5. The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.